<DOC>
	<DOC>NCT02663609</DOC>
	<brief_summary>Chart review study to collect patient data from medical charts of patients who have been treated with Korlym® for the treatment of ACTH independent adrenal Cushing's Syndrome.</brief_summary>
	<brief_title>Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome</brief_title>
	<detailed_description>A retrospective, multi-center, chart review study to collect patient data from medical charts of patients who have been treated with Korlym® for the treatment of ACTH independent adrenal Cushing's Syndrome. Treatment with Korlym® will be a minimum 3 months in duration with follow-up of a minimum 3 months. Only sites that have been identified to have patients appropriate for this protocol will be invited to participate.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Cushing Syndrome</mesh_term>
	<criteria>Diagnosed with ACTH independent endogenous Cushing's Syndrome Available adrenal imaging prior to being treated with Korlym® Treated with Korlym® and followed for at least 3 months (followup data should be available) Diagnosed with adrenocortical carcinoma Participant in any clinical trial(s) during the observational period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Cushing's Syndrome</keyword>
	<keyword>Mifepristone</keyword>
	<keyword>Adrenal</keyword>
	<keyword>Retrospective</keyword>
	<keyword>Chart Review</keyword>
</DOC>